Lipid carriers for mRNA delivery

Zhang, Wanting; Jiang, Yuxin; He, Yonglong; Boucetta, Hamza; Wu, Jun; Chen, Zhongjian; He, Wei

doi:10.1016/j.apsb.2022.11.026

Cited by 34 publications

(16 citation statements)

References 257 publications

(344 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, the vast majority of strategies for NP-mediated modulation of gene expression within cells have relied on the delivery of gene-encoding plasmids, mRNA, or CRISPR. Indeed, the recently developed COVID-19 vaccines (mRNA-based liposomal NPs to direct the synthesis of SARS-CoV-2 spike protein) highlight the utility of NP carriers for controlled cellular gene expression. − One area, however, that remains ripe for exploration is the use of NPs for the extracellular induction of intracellular signaling and gene expression. There are numerous literature examples of the latter, particularly in the context of NP-mediated activation of G-protein-coupled receptors (reviewed in Ma et al) .…”

Section: Discussionmentioning

confidence: 99%

Multivalent Display of Erythropoietin on Quantum Dots Enhances Aquaporin-4 Expression and Water Transport in Human Astrocytes In Vitro

Rogers,

Nag,

Stewart

et al. 2023

Bioconjugate Chem.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Multivalent Display of Erythropoietin on Quantum Dots Enhances Aquaporin-4 Expression and Water Transport in Human Astrocytes In Vitro

Rogers,

Nag,

Stewart

et al. 2023

Bioconjugate Chem.

View full text Add to dashboard Cite

“…LNPs comprise ionizable lipids, phospholipids, cholesterol, and PEG-lipid conjugate. All lipid components have their specific functions [ 77 , 78 ]. The phospholipids (distearoyl phosphatidylcholine (DSPC), dipalmitoyl phosphatidylcholine (DPPC)) form the basic backbone of lipid bilayers; cholesterol is mainly used to regulate the rigidity and mobility of liposomes and to stabilize the structure of liposomes; ionizable lipids have pKa of 6–7 and contain amino groups such as G0-C14 and C12-200.…”

Section: Liposomes and Lipid Nanoparticles (Lnps)mentioning

confidence: 99%

Approved Nanomedicine against Diseases

Jia

Jiang

et al. 2023

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Nanomedicine is a branch of medicine using nanotechnology to prevent and treat diseases. Nanotechnology represents one of the most effective approaches in elevating a drug‘s treatment efficacy and reducing toxicity by improving drug solubility, altering biodistribution, and controlling the release. The development of nanotechnology and materials has brought a profound revolution to medicine, significantly affecting the treatment of various major diseases such as cancer, injection, and cardiovascular diseases. Nanomedicine has experienced explosive growth in the past few years. Although the clinical transition of nanomedicine is not very satisfactory, traditional drugs still occupy a dominant position in formulation development, but increasingly active drugs have adopted nanoscale forms to limit side effects and improve efficacy. The review summarized the approved nanomedicine, its indications, and the properties of commonly used nanocarriers and nanotechnology.

show abstract

“…Different lipid‐based nanocarriers, such as liposomes, LNPs, and cationic nanoemulsions (CNEs), have been extensively investigated for mRNA delivery in preclinical studies and clinical trials (Table S1, Supporting Information). [ 92 ] Among them, LNPs are the most widely investigated and most clinically advanced non‐viral mRNA nanocarriers. The first two approved mRNA vaccines, BNT162b2 and mRNA‐1273, as well as most of the mRNA therapeutics in clinical trials have employed LNPs as delivery systems (Table S1, Supporting Information).…”

Section: Types Of Mrna Cargos and Delivery Systemsmentioning

confidence: 99%

Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery

Huang,

Deng,

Wang

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Messenger RNA (mRNA)‐based therapy has emerged as a powerful, safe, and rapidly scalable therapeutic approach that involves technologies for both mRNA itself and the delivery vehicle. Although there are some unique challenges for different applications of mRNA therapy, a common challenge for all mRNA therapeutics is the transport of mRNA into the target cell cytoplasm for sufficient protein expression. This review is focused on the behaviors at the cellular level of nanotechnology‐mediated mRNA delivery systems, which have not been comprehensively reviewed yet. First, the four main therapeutic applications of mRNA are introduced, including immunotherapy, protein replacement therapy, genome editing, and cellular reprogramming. Second, common types of mRNA cargos and mRNA delivery systems are summarized. Third, strategies to enhance mRNA delivery efficiency during the cellular trafficking process are highlighted, including accumulation to the cell, internalization into the cell, endosomal escape, release of mRNA from the nanocarrier, and translation of mRNA into protein. Finally, the challenges and opportunities for the development of nanotechnology‐mediated mRNA delivery systems are presented. This review can provide new insights into the future fabrication of mRNA nanocarriers with desirable cellular trafficking performance.

show abstract

Lipid carriers for mRNA delivery

Cited by 34 publications

References 257 publications

Multivalent Display of Erythropoietin on Quantum Dots Enhances Aquaporin-4 Expression and Water Transport in Human Astrocytes In Vitro

Multivalent Display of Erythropoietin on Quantum Dots Enhances Aquaporin-4 Expression and Water Transport in Human Astrocytes In Vitro

Approved Nanomedicine against Diseases

Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery

Contact Info

Product

Resources

About